Evaluation of Sharpunkha's Efficacy in Splenomegaly- A Research Report

Area of Science:

• Ayurvedic medicine
• Pharmacology
• Hepatology

Background:

• Splenomegaly, often linked to liver cirrhosis, causes significant hematological and structural issues.
• Current treatments for splenomegaly are often limited, necessitating exploration of alternative therapies.

Purpose of the Study:

• To investigate the therapeutic potential of Tephrosia purpurea (Sharpunkha) for liver cirrhosis-induced splenomegaly.
• To compare the efficacy of Sharpunkha Panchanga Churna and Sharpunkha Panchanga Kshara against Silymarin.

Main Methods:

• An experimental model of thioacetamide-induced splenomegaly in Wistar albino rats was utilized.
• Animals were treated with Sharpunkha Panchanga Churna and Sharpunkha Panchanga Kshara.
• Assessment included anatomical and histological changes, liver function tests (LFT), and complete blood count (CBC).

Main Results:

• Sharpunkha Panchanga Kshara demonstrated superior efficacy in reducing splenic hyperplasia and hepatic fibrosis compared to the Churna.
• The effects of Sharpunkha Panchanga Kshara were comparable to the standard drug, Silymarin.
• Histological analysis revealed improvements in spleen and liver architecture post-treatment.

Conclusions:

• Tephrosia purpurea, particularly Sharpunkha Panchanga Kshara, shows significant therapeutic potential for managing splenomegaly associated with liver cirrhosis.
• Findings support the traditional Ayurvedic classification of Sharpunkha as 'Pleehashatru' (enemy of the spleen).
• Clinical trials are warranted to confirm the efficacy of Sharpunkha in hepatosplenomegaly management.